The Global PuraStat Dinner Grandior Hotel Prague on Thursday 28th April 2022

On Thursday 28th April 2022, 3-D Matrix, in collaboration with FUJIFILM, hosted their first global PuraStat gala dinner since the covid-19 pandemic began. The event took place at the Grandior Hotel Prague from 20:00 until 22:00.

Chaired by Prof. Pradeep Bhandari (Queen Alexandra Hospital, UK) and Prof. Alessandro Repici (Humanitas Research Hospital, Italy), the night started with a dinner buffet where endoscopists mingled and networked, followed by presentation discussions and a selection of desserts and drinks.

The discussion session consisted of an exciting line-up of presentations from Dr Eduardo Albéniz (Complejo Hospitalario de Navarra, Spain), Dr Marietta Iacucci (Queen Elizabeth Hospital Birmingham, UK), Assoc. Prof. Štěpán Suchánek (Military University Hospital Prague, Czech Republic) and lastly, Prof. Pradeep Bhandari.

Dr Eduardo Albéniz kicked off the presentations with a brief introduction about the PuraStat history, diving into the peptide technology behind it and its current uses in gastrointestinal (GI) procedures as a haemostatic agent. He touched on the scientific data showing the impact of PuraStat in radiation proctopathy as well as in the treatment of solitary rectal ulcer syndrome and further emphasised the ongoing clinical studies.

Dr Marietta Iacucci followed with examples of PuraStat used in a clinical setting. She shared her experience of using PuraStat to prevent delayed bleeding within endoscopic mucosal resection (EMR)* and endoscopic submucosal dissection (ESD) and to achieve haemostasis of GI bleeding.

Through a series of photos and case videos, Assoc. Prof. Štěpán Suchánek told us about his experience of using PuraStat to treat post-resection mucosal defects after endoscopic procedures. This showed that PuraStat could have properties beyond just a haemostat.

Prof Pradeep Bhandari finished the session with the latest results from the Prospective Observational PuraStat Study (POPS) UK. PuraStat was used to treat a range of indications including radiation proctitis, GAVE, angiodysplasia, peptic ulcer bleeds, and sphincterotomy bleeds, with most of the patients being high-risk patients in EMR/knife-assisted resection (KAR) and ESD procedures. He summarised that 3mL of PuraStat was sufficient to control most intraprocedural bleeds and that overall, the study showed a low delayed bleed rate in his patients.

In summary, the event was a great success, providing endoscopists with insight into the latest data behind PuraStat which captured more potential users.

*Note: this is not an indication of PuraStat. Please read carefully the instructions for use, contraindications and warnings.

Watch the full recording [here]

Back to Blog